Vytorin Price Will Be Key To Impact In Cholesterol Market, AstraZeneca Says

The uptake of Vytorin (ezetimibe/simvastatin) will depend on the pricing strategy adopted by Merck and Schering-Plough, AstraZeneca CEO Tom McKillop predicted during a July 22 earnings call

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet